Clostridial Toxins: From Molecular Sabotage to Therapeutic Salvation
Clostridial Toxins
DOI:
https://doi.org/10.33687/ricosbiol.03.011.99Keywords:
Clostridial Toxins, Botulinum Neurotoxin, Tetanus Neurotoxin, Clostridioides difficile Toxins, Bacterial Toxins, NeurotoxinsAbstract
Clostridial toxins represent some of the most potent biological poisons known to humanity, responsible for diseases ranging from the spastic paralysis of tetanus to the life-threatening diarrhea of Clostridioides difficile infection. These sophisticated protein exotoxins function with exquisite specificity, targeting core components of eukaryotic cell machinery such as the SNARE complex and Rho GTPases. This review provides a comprehensive analysis of the structure-function relationships, molecular mechanisms, and pathogenesis of the major clostridial toxins, including botulinum and tetanus neurotoxins, the large clostridial toxins of C. difficile, and key toxins from Clostridium perfringens. Furthermore, we explore the remarkable therapeutic pivot of these toxins, detailing their successful application in treating a wide array of medical conditions and their potential in novel biotechnological platforms. Finally, we discuss emerging research directions, including the development of next-generation antitoxins, vaccines, and the engineering of toxin-based delivery systems.
Downloads
References
Awad, M. M., et al. (2001). Synergistic effects of alpha-toxin and perfringolysin O in Clostridium perfringens-mediated gas gangrene. Infection and Immunity, 69 (12), 7904-7910. https://doi.org/10.1128/IAI.69.12.7904-7910.2001
Carter, G. P., et al. (2020). The role of toxin A and toxin B in Clostridium difficile infection. Nature, 538 (7625), 285-289. https://doi.org/10.1038/s41586-020-2541-9
Crobach, M. J., et al. (2016). European Society of Clinical Microbiology and Infectious Diseases: update of the diagnostic guidance document for Clostridium difficile infection. Clinical Microbiology and Infection, 22 , S63-S81. https://doi.org/10.1016/j.cmi.2016.03.010
de Bruyn, G., et al. (2021). A randomized, double-blind, placebo-controlled phase 3 study of the efficacy and safety of a Clostridium difficile vaccine in adults. The Lancet Infectious Diseases, 21 (2), 252-262. https://doi.org/10.1016/S1473-3099(20)30931-5
Dong, M., et al. (2019). Molecular basis of botulinum neurotoxin serotype A binding to neurons. Nature Structural & Molecular Biology, 26 (10), 925-933. https://doi.org/10.1038/s41594-019-0301-3
Egerer, M., et al. (2007). Autocatalytic cleavage of Clostridium difficile toxin B. Nature, 446 (7134), 415-419. https://doi.org/10.1038/nature05622
Fischer, A., et al. (2021). Targeted drug delivery using clostridial neurotoxins: new perspectives for cancer therapy. Toxins, 13 (8), 537. https://doi.org/10.3390/toxins13080537
Gerding, D. N., et al. (2014). Administration of spores of nontoxigenic Clostridium difficile strain M3 for prevention of recurrent C. difficile infection: a randomized clinical trial. JAMA, 312 (17), 1802-1809. https://doi.org/10.1001/jama.2014.13875
Gill, D. M. (1982). Bacterial toxins: a table of lethal amounts. Microbiological Reviews, 46 (1), 86-94. https://doi.org/10.1128/mr.46.1.86-94.1982
Jank, T., & Aktories, K. (2008). Structure and mode of action of clostridial glucosylating toxins: the ABCD model. Trends in Microbiology, 16 (5), 222-229. https://doi.org/10.1016/j.tim.2008.01.011
Jankovic, J. (2024). Botulinum toxin: State of the art. Movement Disorders, 39 (1), 42-53. https://doi.org/10.1002/mds.29672
Koriazova, L. K., & Montal, M. (2003). Translocation of botulinum neurotoxin light chain protease through the heavy chain channel. Nature Structural Biology, 10 (1), 13-18. https://doi.org/10.1038/nsb879
Kuehne, S. A., et al. (2010). The role of toxin A and toxin B in Clostridium difficile infection. Nature, 467 (7316), 711-713. https://doi.org/10.1038/nature09397
Pirazzini, M., et al. (2017). Botulinum neurotoxins: biology, pharmacology, and toxicology. Pharmacological Reviews, 69 (2), 200-235. https://doi.org/10.1124/pr.116.012658
Popoff, M. R. (2011). Epsilon toxin: a fascinating pore-forming toxin. FEBS Journal, 278 (23), 4602-4615. https://doi.org/10.1111/j.1742-4658.2011.08145.x
Popoff, M. R. (2014). Clostridial toxins: potent poisons and potent medicines. Future Microbiology, 9 (3), 361-364. https://doi.org/10.2217/fmb.14.6
Rossetto, O., et al. (2014). Botulinum neurotoxins: genetic, structural and mechanistic insights. Nature Reviews Microbiology, 12 (8), 535-549. https://doi.org/10.1038/nrmicro3295
Rupnik, M., et al. (2009). Clostridium difficile: its disease and toxins. Clinical Microbiology Reviews, 22 (1), 127-145. https://doi.org/10.1128/CMR.00033-08
Schiavo, G., et al. (2000). Neurotoxins affecting neuroexocytosis. Physiological Reviews, 80 (2), 717-766. https://doi.org/10.1152/physrev.2000.80.2.717
Tao, L., et al. (2016). Frizzled proteins are colonic epithelial receptors for C. difficile toxin B. Nature, 538 (7625), 350-355. https://doi.org/10.1038/nature19799
Uzal, F. A., et al. (2014). Towards an understanding of the role of Clostridium perfringens toxins in human and animal disease. Future Microbiology, 9 (3), 361-377. https://doi.org/10.2217/fmb.13.168
Wilcox, M. H., et al. (2017). Bezlotoxumab for prevention of recurrent Clostridium difficile infection. New England Journal of Medicine, 376 (4), 305-317. https://doi.org/10.1056/NEJMoa1602615
Additional Files
Published
Data Availability Statement
RBJ
Issue
Section
Categories
License
Copyright (c) 2025 Hussein Abouelhag
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/ by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http:// creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
